Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AB928 + Pegylated liposomal-doxorubicin|
AB928 is an antagonist of the adenosine receptors A2aR and A2bR, which may relieve adenosine-mediated immune suppression and lead to enhanced anti-tumor activity in combination with other agents (European Journal of Cancer, Vol 92, S14-S15).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AB928||AB 928|AB-928|Etrumadenant||Adenosine Targeting 16||AB928 (etrumadenant) is an antagonist of the adenosine receptors A2aR and A2bR, which may relieve adenosine-mediated immune suppression and lead to enhanced anti-tumor activity in combination with other agents (European Journal of Cancer, Vol 92, S14-S15, PMID: 30569245).|
|Pegylated liposomal-doxorubicin||Doxil||ATI-0918|CAELYX||Chemotherapy - Anthracycline 11||Doxil (pegylated liposomal doxorubicin) is doxorubicin (intercalates into DNA, disrupting DNA replication) encapsulated, which within a liposome allows better penetration into tumors, decreases toxicity, and increases the period of effectiveness, and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03719326||Phase I||AB928 + IPI-549 + Pegylated liposomal-doxorubicin AB928 + Pegylated liposomal-doxorubicin||A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies||Active, not recruiting||USA||1|